Page 5 - Drug Makers In India

Govt probe into bribery claim in toxic syrup tests nears completion: Report

Indian-made cough syrups have been linked to the deaths of at least 141 children in Gambia, Uzbekistan and Cameroon since last year

Over 2.9k drugs found to be substandard in tests conducted in 2022-23: Govt

Out of the 89,729 drug samples tested between April 2022 and March 2023, 2,921 drugs were found to be "not of standard quality" while 422 were identified as spurious, the Rajya Sabha was told on Tuesday. In a written reply, Minister of State for Health Bharati Pravin Pawar said 642 prosecutions were launched for manufacturing, sale and distribution of spurious/adulterated drugs, while 262 persons were arrested during the same period as per information received from drugs controllers of various states and Union territories. This excludes data from Rajasthan. Giving details of the previous year, Pawar said a total 88,844 samples were tested between April 2021 and March 2022 of which 2,545 were declared to be not of standard quality while 379 were found to be spurious. She said 592 prosecutions were launched for manufacturing, sale and distribution of spurious/adulterated drugs and 450 persons arrested during the same period. Responding to a question, Pawar said that in order to asse

Zydus Lifesciences receives USFDA approval for Ivabradine tablets

On Friday, shares of Zydus Lifesciences were up/down by 0.34 per cent, ending the day's trade at Rs 640 apiece on the BSE

Sun Pharma and Zydus Lifesciences partner to market kidney drug Desidustat

Under this licensing agreement, Zydus has granted Sun Pharma semi-exclusive rights to co-market Desidustat in India

Sanofi loses $21 bn in market value after dropping 2025 profit target

Sanofi shares trade at a 12 month forward price-to-earnings ratio of 11, a discount to AstraZeneca's 16 and global pharma index of 17, according to LSEG data

Maharashtra has become big market for sale, consumption of drugs: Saamana

Saamana claimed that the drugs that are not being seized by the authorities at the ports of Gujarat are being released into Maharashtra

Drug regulatory reforms for improving quality

A strong drug regulation system is essential for India, as it not only supplies quality drugs to its own population but is responsible for meeting 20 per cent of the global demand

PLI scheme effect? Bulk drug imports from China slow, shows data

Experts say scheme to boost local manufacturing will take 5-7 years to show tangible results

Drug regulator CDSCO finds syrups made by Norris Medicines toxic: Report

The drug regulator for Gujarat state, where Norris is based, told Reuters that its factory had been closed

WHO's good manufacturing norms to be made compulsory for all drug firms

Only 2,000 of the 10,500 manufacturing units in the country have the World Health Organization's GMP certification

DCGI asks states to keep vigil on sale of falsified versions of 2 drugs

The Drugs Controller General of India (DCGI) has directed the drugs controllers of all states and Union territories to keep a strict vigil on the sale and distribution of falsified versions of two drugs, liver medication Defitelio and Takeda's cancer drug Adcetris (injection), following alerts issued by the World Health Organisation (WHO). In an advisory on September 5, the DCGI said the WHO has issued a safety alert identified with multiple falsified versions of Adcetris injection 50 mg manufactured by Takeda Pharmaceutical Company Limited, identified in four different countries including India. "These products are most often available at the patient level and distributed in the unregulated supply chains (mainly online). The products have been identified in both regulated and illicit supply chains, sometimes at patient levels as well. WHO has reported that there are at least eight different batch numbers of falsified versions in circulation," the DCGI said in a communication to the

DCGI warns against use of pholcodine-containing cough syrups, cites risks

Regulator asks doctors to suggest an alternative to patients for treating their symptoms

World Drug Day 2023: Theme, History, Importance and More about drug abuse

The purpose of this World Drug Day 2023 campaign is to spread awareness of the significance of treating people using drugs with respect and compassion

Indiana Ophthalmics faces CDSCO probe; Pharmexcil may suspend membership

CDSCO starts probe based in complaint by Sri Lanka that eyedrops made by the firm are linked to eye infections in more than 30 people

Contaminated drugs: USFDA uncovers failures in India's pharma factories

The $50 billion sector is under the spotlight after a number of recent scandals linked to smaller, privately-held Indian companies, including the deaths of dozens of children in Gambia and Uzbekistan

Pharma industry seeks graded introduction of trade margin rationalisation

TMR may be applied in phases, with the first one including drugs priced above Rs 100 or so

Drug sales stuck at pre-pandemic level, price rise shapes market growth

Respiratory medicines doing well as people recover from long-term effects of Covid-19

DCGI asks drug manufacturers not to use propylene glycol by Delhi firm

India's drug regulator has directed drug manufacturers not to use propylene glycol supplied by a Delhi-based company which provided the ingredient to Marion Biotech, whose cough syrups were alleged to have led to the deaths of children in Uzbekistan. Maya Chemtech India Pvt. Ltd. supplied propylene glycol used in Marion Biotech's cough syrups that were found to be "not of standard quality", according to the regulator. Three employees of Marion Biotech were arrested on charges of manufacture and sale of adulterated drugs. Also, the drugs inspector from the Central Drugs Standard Control Organisation (CDSCO) North Zone last week issued a notice to the pharmaceutical firm asking it to stop the sale and distribution of the drug concerned, stating that the sample was found to be "not of standard quality". Uzbekistan alleged in December last year that several children died after consuming Marion Biotech's cough syrups, which it claimed were contaminated with unacceptable amounts of ethyl

Analysts turn cautious on Cipla as US FDA action delays key US launches

Analysts believe that some of the recent observations from the US FDA are critical in nature and could lead to a potential Official Action Indicated (OAI) classification for the Indore plant

India needs regulatory data protection for drug research: Novartis CEO

India should have a regulatory data protection system in place to attract fundamental drug research from major pharmaceutical companies in the world, Novartis Chief Executive Officer Vasant Narasimhan said on Friday here. Speaking to reporters on the sidelines of the life sciences conclave 'BioAsia 2023' being held here, Narasimhan said great work has been done to streamline Intellectual Property (IP) issues which can be further improved. "I think the next step is when you think about how we generate data and how protected that is in regulatory filings. India does not have regulatory data protection," he said replying to a query. If one looks at any place in the world where there is significant fundamental drug research happening from multinational firms, there is regulatory data protection, including China, Narasimhan further said. The Novartis CEO added that getting approvals for clinical trials used to be very difficult in India earlier. However, with the new policy, the process